Sohkichi Matsumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sohkichi Matsumoto has a total of 529 co-authors. Here are the top co-authors by number of shared publications:
Yuriko Ozeki
Department of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan
24 shared publicationsYoshitaka Tateishi
Department of Microbiology, Fukushima Medical University, 1Hikariga-oka Fukushima City, 960-1295, Japan
23 shared publicationsTakeshi Yamada
Microbiology and Oral Infection, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
21 shared publicationsKazuo Kobayashi
Department of Immunology, National Institute of Infectious Diseases, Tokyo, Japan
18 shared publications- Mariko Naito
Department of Microbiology and Oral Infection, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
12 shared publications Akihito Nishiyama
Department of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan
11 shared publications
Latest Publications
- 24 August 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1452
Comparative whole genome analysis of Mycobacterium tuberculosis isolated from BPaLM and individualized regimen treated patients at Dr. Soetomo Hospital, Indonesia
Background The World Health Organization (WHO) recommends whole genome sequencing (WGS) to support the detection of drug-resistant tuberculosis and the use of the new regimen BPaLM (Bedaquiline-Pretomanid-Linezolid-Moxifloxacin) to treat drug-resistant tuberculosis (TB). Genomic profiles of Mycobacterium tuberculosis (MTB) are needed to understand the regimen’s future impact comprehensively. Methods In this study, we performed WGS to Mycobacterium tuberculosis isolates from rifampicin resistant tuberculosis patients at Dr. Soetomo Hospital. A total of 15 samples consisting of 14 clinical isolate samples (8 BPaLM and 6 Individualized treated patients) and one laboratory H37Rv reference strain were sequenced using the Illumina MiSeq platform and analyzed using Galaxy, TBProfiler, Mykrobe, and ResFinder. Results Lineage analysis revealed that L2.2 was the predominant strain (48%), followed by L4, L4.3, L2.1, and L1.2. Most rifampicin-resistant and multidrug-resistant strains were associated with the East Asian Beijing lineage, with a smaller proportion linked to Euro-American lineages. The TBProfiler and Mykrobe demonstrated higher sensitivity than ResFinder (86% versus 79%), while all tools showed high specificity. Resistance associated mutations were primarily identified in rpoB, katG, embB, and pncA, with single nucleotide variants being the most common. This study has a limited number of representative clinical isolates, thus representing further study with a greater number of population sample of both groups. Conclusions Beijing lineage strains predominated and were associated with increased drug resistance. Variants in efflux regulatory genes may contribute to the emergence of multidrug-resistant strains. The Mann–Whitney U test revealed no statistically significant difference between the two groups, with a p-value of 0.4136 (p > 0.05). Furthermore, genomic analysis revealed that the BPALM group exhibited a lower burden of single nucleotide polymorphisms (SNPs) and fewer unique cumulative genetic variants than the Individualized treatment group.
- 24 August 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1452
Comparative whole genome analysis of Mycobacterium tuberculosis isolated from BPaLM and individualized regimen treated patients at Dr. Soetomo Hospital, Indonesia
Background The World Health Organization (WHO) recommends whole genome sequencing (WGS) to support the detection of drug-resistant tuberculosis and the use of the new regimen BPaLM (Bedaquiline-Pretomanid-Linezolid-Moxifloxacin) to treat drug-resistant tuberculosis (TB). Genomic profiles of Mycobacterium tuberculosis (MTB) are needed to understand the regimen’s future impact comprehensively. Methods In this study, we performed WGS to Mycobacterium tuberculosis isolates from rifampicin resistant tuberculosis patients at Dr. Soetomo Hospital. A total of 15 samples consisting of 14 clinical isolate samples (8 BPaLM and 6 Individualized treated patients) and one laboratory H37Rv reference strain were sequenced using the Illumina MiSeq platform and analyzed using Galaxy, TBProfiler, Mykrobe, and ResFinder. Results Lineage analysis revealed that L2.2 was the predominant strain (48%), followed by L4, L4.3, L2.1, and L1.2. Most rifampicin-resistant and multidrug-resistant strains were associated with the East Asian Beijing lineage, with a smaller proportion linked to Euro-American lineages. The TBProfiler and Mykrobe demonstrated higher sensitivity than ResFinder (86% versus 79%), while all tools showed high specificity. Resistance associated mutations were primarily identified in rpoB, katG, embB, and pncA, with single nucleotide variants being the most common. This study has a limited number of representative clinical isolates, thus representing further study with a greater number of population sample of both groups. Conclusions Beijing lineage strains predominated and were associated with increased drug resistance. Variants in efflux regulatory genes may contribute to the emergence of multidrug-resistant strains. The Mann–Whitney U test revealed no statistically significant difference between the two groups, with a p-value of 0.4136 (p > 0.05). Furthermore, genomic analysis revealed that the BPALM group exhibited a lower burden of single nucleotide polymorphisms (SNPs) and fewer unique cumulative genetic variants than the Individualized treatment group.
- Open Access
- 27 July 2026
- Published by Wiley in Microbiology and Immunology
- Vol. 70 (10) , 493-503
Mycobacterium intracellulare M.i.198—A Promising Strain for Studying Pathogenesis of Nontuberculous Mycobacterial Pulmonary Disease (NTM‐PD)
In this review, we introduce a promising strain for studying pathogenesis of nontuberculous mycobacterial pulmonary disease (NTM‐PD), Mycobacterium intracellulare M.i.198. M.i.198 was isolated from a patient with progressive Mycobacterium avium‐intracellulare complex pulmonary disease (MAC‐PD) in whom surgical operation was required to suppress disease progression. M.i.198 shows progressive illness in infected mice in terms of bacterial load, inflammation, and by high‐dose inoculation, mortality as well. Although M.i.198 is resistant to clarithromycin, the pathogenicity of M.i.198 in mice indicates the high potency for use to evaluate drug efficacies in vivo. Furthermore, M.i.198 can be genetically manipulated, which is quite different from other MAC strains, especially those of M. avium subsp. hominissuis . We herein report the bacteriological findings, experimental virulence and functional genomic features of M.i.198 with a small review of MAC strains used for animal models of MAC‐PD.
- 27 July 2026
- Published by Wiley in Microbiology and Immunology
- Vol. 70 (10) , 493-503
Open AccessMycobacterium intracellulare M.i.198—A Promising Strain for Studying Pathogenesis of Nontuberculous Mycobacterial Pulmonary Disease (NTM‐PD)
In this review, we introduce a promising strain for studying pathogenesis of nontuberculous mycobacterial pulmonary disease (NTM‐PD), Mycobacterium intracellulare M.i.198. M.i.198 was isolated from a patient with progressive Mycobacterium avium‐intracellulare complex pulmonary disease (MAC‐PD) in whom surgical operation was required to suppress disease progression. M.i.198 shows progressive illness in infected mice in terms of bacterial load, inflammation, and by high‐dose inoculation, mortality as well. Although M.i.198 is resistant to clarithromycin, the pathogenicity of M.i.198 in mice indicates the high potency for use to evaluate drug efficacies in vivo. Furthermore, M.i.198 can be genetically manipulated, which is quite different from other MAC strains, especially those of M. avium subsp. hominissuis . We herein report the bacteriological findings, experimental virulence and functional genomic features of M.i.198 with a small review of MAC strains used for animal models of MAC‐PD.
- Open Access
- 15 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Real-time bioluminescence imaging of mycobacteria with Akaluc: a novel method for monitoring drug efficacy
Tuberculosis (TB) still threatens human life despite the availability of childhood vaccination and modern treatment regimens due to the emergence of tuberculosis with extended resistance profiles. The mouse active TB model remains the gold standard for evaluating anti-TB drugs and vaccines. However, in vivo experiments raise ethical concerns and are time-consuming. We established an Akaluc-based bioluminescence platform to enable rapid drug screening in culture media and THP‑1 cells. Codon-optimized Akaluc expression in mycobacteria was accomplished by assortment of vectors and promoters. Bioluminescence kinetics were evaluated in culture media and THP‑1 cells with or without drug treatment, and optimized by adjusting time points and substrate concentrations. TokeOni at a concentration of 10 nM/100 µL produced the highest bioluminescence compared to other tested concentrations and substrates. Among the tested promoter-plasmid constructs, the Ag85B promoter in pMV261 generated the strongest bioluminescence in Mycobacterium smegmatis and Mycobacterium bovis. Bioluminescence fluctuated with bacterial growth, peaking during the log phase and gradually declining during the stationary phase. A positive correlation was observed between bioluminescence and CFU reduction in vitro upon treatment with sensitive drugs.
- 15 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessReal-time bioluminescence imaging of mycobacteria with Akaluc: a novel method for monitoring drug efficacy
Tuberculosis (TB) still threatens human life despite the availability of childhood vaccination and modern treatment regimens due to the emergence of tuberculosis with extended resistance profiles. The mouse active TB model remains the gold standard for evaluating anti-TB drugs and vaccines. However, in vivo experiments raise ethical concerns and are time-consuming. We established an Akaluc-based bioluminescence platform to enable rapid drug screening in culture media and THP‑1 cells. Codon-optimized Akaluc expression in mycobacteria was accomplished by assortment of vectors and promoters. Bioluminescence kinetics were evaluated in culture media and THP‑1 cells with or without drug treatment, and optimized by adjusting time points and substrate concentrations. TokeOni at a concentration of 10 nM/100 µL produced the highest bioluminescence compared to other tested concentrations and substrates. Among the tested promoter-plasmid constructs, the Ag85B promoter in pMV261 generated the strongest bioluminescence in Mycobacterium smegmatis and Mycobacterium bovis. Bioluminescence fluctuated with bacterial growth, peaking during the log phase and gradually declining during the stationary phase. A positive correlation was observed between bioluminescence and CFU reduction in vitro upon treatment with sensitive drugs.
- Open Access
- 1 February 2026
- Published by Springer Nature in Research Square
Muse cell known as a kind of Stem cell enabled therapy for SARS-CoV-2-Lung and Olfactory Impairment in Syrian Hamsters and may also have therapeutic effects for long COVID
Background Long COVID, including symptoms such as asthma, allergies, musculoskeletal pain, diabetes, insomnia, headaches, chronic fatigue, and frailty persisting for at least 2 months following acute SARS-CoV-2 infection, is a global health concern with no established treatments. While some studies demonstrated efficacy using mesenchymal stem cells (MSCs), outcomes have been inconsistent. Methods In the present study, we evaluated a small, distinct subset of SSEA-3(+) MSCs, known as multilineage-differentiating stress-enduring (Muse) cells, in a preclinical model of SARS-CoV-2 infection. Here, in a Syrian hamster model of SARS-CoV-2 infection, Syrian hamsters were intranasally inoculated with SARS-CoV-2 on day 0, and then on day 2, the hamsters were intravenously administered Muse cells, non-Muse cells, or vehicle (saline). On day 8, the hamsters were sacrificed, and the lungs and olfactory bulb (OB) were removed from the body to perform the experiments including inflammatory response, apoptosis, fibrosis (lung only). At the same time, total RNA was extracted from the lung and OB for RNA-seq and IPA analysis. Results We demonstrated that intravenous treatment with human-bone marrow-derived Muse cells more effectively reduced inflammation, fibrosis, and apoptosis than non-Muse-MSCs while preserving oxygen saturation, body weight, lung and olfactory bulb structure, and alveolar air space. RNA sequencing identified 64 differentially expressed genes associated with Muse cell-mediated tissue protection, with distinct profiles in olfactory bulb and lung tissues. Although this study does not directly assess long COVID, the marked suppression of severe COVID-associated pathology suggests that Muse cell treatment holds promise as a potential therapeutic approach for long COVID. Conclusions Our findings demonstrated that Muse cells suppressed the expression of inflammatory, apoptosis, fibrosis mediators that may exacerbate severe COVID-19 pathology as ARDS. Some reports suggest that SARS-CoV-2 infection in the olfactory bulb provides a route for SARS-CoV-2 viral invasion of the brain, leading to neurologic symptoms of long COVID. Therefore, we propose that Muse cells could ameliorate both pulmonary and neurologic components of long COVID by suppressing key inflammatory and fibrotic pathways. Because Finally, these findings suggest that Muse cells may be a promising therapeutic approach for mitigating the symptoms of severe COVID-19 infection and preventing long COVID.
- 1 February 2026
- Published by Springer Nature in Research Square
Open AccessMuse cell known as a kind of Stem cell enabled therapy for SARS-CoV-2-Lung and Olfactory Impairment in Syrian Hamsters and may also have therapeutic effects for long COVID
Background Long COVID, including symptoms such as asthma, allergies, musculoskeletal pain, diabetes, insomnia, headaches, chronic fatigue, and frailty persisting for at least 2 months following acute SARS-CoV-2 infection, is a global health concern with no established treatments. While some studies demonstrated efficacy using mesenchymal stem cells (MSCs), outcomes have been inconsistent. Methods In the present study, we evaluated a small, distinct subset of SSEA-3(+) MSCs, known as multilineage-differentiating stress-enduring (Muse) cells, in a preclinical model of SARS-CoV-2 infection. Here, in a Syrian hamster model of SARS-CoV-2 infection, Syrian hamsters were intranasally inoculated with SARS-CoV-2 on day 0, and then on day 2, the hamsters were intravenously administered Muse cells, non-Muse cells, or vehicle (saline). On day 8, the hamsters were sacrificed, and the lungs and olfactory bulb (OB) were removed from the body to perform the experiments including inflammatory response, apoptosis, fibrosis (lung only). At the same time, total RNA was extracted from the lung and OB for RNA-seq and IPA analysis. Results We demonstrated that intravenous treatment with human-bone marrow-derived Muse cells more effectively reduced inflammation, fibrosis, and apoptosis than non-Muse-MSCs while preserving oxygen saturation, body weight, lung and olfactory bulb structure, and alveolar air space. RNA sequencing identified 64 differentially expressed genes associated with Muse cell-mediated tissue protection, with distinct profiles in olfactory bulb and lung tissues. Although this study does not directly assess long COVID, the marked suppression of severe COVID-associated pathology suggests that Muse cell treatment holds promise as a potential therapeutic approach for long COVID. Conclusions Our findings demonstrated that Muse cells suppressed the expression of inflammatory, apoptosis, fibrosis mediators that may exacerbate severe COVID-19 pathology as ARDS. Some reports suggest that SARS-CoV-2 infection in the olfactory bulb provides a route for SARS-CoV-2 viral invasion of the brain, leading to neurologic symptoms of long COVID. Therefore, we propose that Muse cells could ameliorate both pulmonary and neurologic components of long COVID by suppressing key inflammatory and fibrotic pathways. Because Finally, these findings suggest that Muse cells may be a promising therapeutic approach for mitigating the symptoms of severe COVID-19 infection and preventing long COVID.
- Open Access
- 23 December 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Functional genomics reveals strain-specific genetic requirements conferring hypoxic growth in Mycobacterium intracellulare
Mycobacterium intracellulare is a major etiological agent of the recently expanding Mycobacterium avium–intracellulare complex pulmonary disease (MAC-PD). Therapeutic regimens that include a combination of macrolides and antituberculous drugs have been implemented with limited success. To identify novel targets for drug development that accommodate the genomic diversity of M. avium–intracellulare , we subjected eight clinical MAC-PD isolates and the type strain ATCC13950 to genome-wide profiling to comprehensively identify universally essential functions by transposon sequencing (TnSeq). Among these strains, we identified 131 shared essential or growth-defect-associated genes by TnSeq. Unlike the type strain, the clinical strains showed increased requirements for genes involved in gluconeogenesis and the type VII secretion system under standard growth conditions, the same genes required for hypoxic pellicle-type biofilm formation in ATCC13950. Consistent with the central role of hypoxia in the evolution of M. intracellulare , the clinical MAC-PD strains showed more rapid adaptation to hypoxic growth than the type strain. Importantly, the increased requirements of hypoxic fitness genes were confirmed in a mouse lung infection model. These findings confirm the concordant genetic requirements under hypoxic conditions in vitro and hypoxia-related conditions in vivo and highlight the importance of using clinical strains and host-relevant growth conditions to identify high-value targets for drug development.
- 23 December 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessFunctional genomics reveals strain-specific genetic requirements conferring hypoxic growth in Mycobacterium intracellulare
Mycobacterium intracellulare is a major etiological agent of the recently expanding Mycobacterium avium–intracellulare complex pulmonary disease (MAC-PD). Therapeutic regimens that include a combination of macrolides and antituberculous drugs have been implemented with limited success. To identify novel targets for drug development that accommodate the genomic diversity of M. avium–intracellulare , we subjected eight clinical MAC-PD isolates and the type strain ATCC13950 to genome-wide profiling to comprehensively identify universally essential functions by transposon sequencing (TnSeq). Among these strains, we identified 131 shared essential or growth-defect-associated genes by TnSeq. Unlike the type strain, the clinical strains showed increased requirements for genes involved in gluconeogenesis and the type VII secretion system under standard growth conditions, the same genes required for hypoxic pellicle-type biofilm formation in ATCC13950. Consistent with the central role of hypoxia in the evolution of M. intracellulare , the clinical MAC-PD strains showed more rapid adaptation to hypoxic growth than the type strain. Importantly, the increased requirements of hypoxic fitness genes were confirmed in a mouse lung infection model. These findings confirm the concordant genetic requirements under hypoxic conditions in vitro and hypoxia-related conditions in vivo and highlight the importance of using clinical strains and host-relevant growth conditions to identify high-value targets for drug development.
- Open Access
- 23 December 2025
- Published by American Society for Microbiology in mSphere
- Vol. 10 (12) , e0046325
Analysis of the drug target of the anti-tuberculosis compound OCT313: phosphotransacetylase is a potential drug target for anti-mycobacterial agents
Tuberculosis (TB) is one of the most common infectious diseases caused by bacteria worldwide. The increasing prevalence of multidrug-resistant TB (MDR-TB) and latent TB infection (LTBI) has intensified the global TB burden. Therefore, the development of new drugs for MDR-TB and LTBI is urgently required. We have reported that the derivative of dithiocarbamate sugar derivative, 2-acetamido-2-deoxy-β-D-glucopyranosyl N,N -dimethyldithiocarbamate (OCT313), exhibits anti-mycobacterial activity against MDR-MTB. Here, we identified the target of OCT313. In experimentally generated OCT313-resistant bacteria, adenine at position 1,092 in the metabolic enzyme phosphotransacetylase (PTA) gene was replaced with cytosine. This mutation is a nonsynonymous mutation that converts methionine to leucine at position 365 in the PTA protein. OCT313 inhibited the enzymatic activity of recombinant wild-type PTA, but not of the mutant PTA (M365L). PTA is an enzyme that produces acetyl-coenzyme A (acetyl-CoA) from acetyl phosphate and CoA and is involved in metabolic pathways; therefore, it was expected to also be active against dormant Mycobacterium tuberculosis bacilli. OCT313 exhibits antibacterial activity in the Wayne model of dormancy using Mycobacterium bovis BCG, and overexpression of PTA in OCT313-resistant bacilli restored sensitivity to OCT313. Collectively, the target of OCT313 is PTA, and OCT313 is a promising antimicrobial candidate for MDR-TB and LTBI. IMPORTANCE: Through this study, we propose a new target for the development of medicines to treat multidrug-resistant tuberculosis and latent tuberculosis infection. The target enzyme phosphotransacetylase (PTA) is a key enzyme that functions in major metabolic pathways, and the homologous structures of PTA enzymes vary greatly among bacterial species. Since the treatment of mycobacterial disease is long term, the development of antibiotics targeting PTA is useful for species-specific therapy.
- 23 December 2025
- Published by American Society for Microbiology in mSphere
- Vol. 10 (12) , e0046325
Open AccessAnalysis of the drug target of the anti-tuberculosis compound OCT313: phosphotransacetylase is a potential drug target for anti-mycobacterial agents
Tuberculosis (TB) is one of the most common infectious diseases caused by bacteria worldwide. The increasing prevalence of multidrug-resistant TB (MDR-TB) and latent TB infection (LTBI) has intensified the global TB burden. Therefore, the development of new drugs for MDR-TB and LTBI is urgently required. We have reported that the derivative of dithiocarbamate sugar derivative, 2-acetamido-2-deoxy-β-D-glucopyranosyl N,N -dimethyldithiocarbamate (OCT313), exhibits anti-mycobacterial activity against MDR-MTB. Here, we identified the target of OCT313. In experimentally generated OCT313-resistant bacteria, adenine at position 1,092 in the metabolic enzyme phosphotransacetylase (PTA) gene was replaced with cytosine. This mutation is a nonsynonymous mutation that converts methionine to leucine at position 365 in the PTA protein. OCT313 inhibited the enzymatic activity of recombinant wild-type PTA, but not of the mutant PTA (M365L). PTA is an enzyme that produces acetyl-coenzyme A (acetyl-CoA) from acetyl phosphate and CoA and is involved in metabolic pathways; therefore, it was expected to also be active against dormant Mycobacterium tuberculosis bacilli. OCT313 exhibits antibacterial activity in the Wayne model of dormancy using Mycobacterium bovis BCG, and overexpression of PTA in OCT313-resistant bacilli restored sensitivity to OCT313. Collectively, the target of OCT313 is PTA, and OCT313 is a promising antimicrobial candidate for MDR-TB and LTBI. IMPORTANCE: Through this study, we propose a new target for the development of medicines to treat multidrug-resistant tuberculosis and latent tuberculosis infection. The target enzyme phosphotransacetylase (PTA) is a key enzyme that functions in major metabolic pathways, and the homologous structures of PTA enzymes vary greatly among bacterial species. Since the treatment of mycobacterial disease is long term, the development of antibiotics targeting PTA is useful for species-specific therapy.
- Open Access
Mycobacterial DNA-binding protein 1 (MDP1) induces RNA condensation as revealed by high-speed AFM
Mycobacterial DNA-binding protein 1 (MDP1) is a histone-like protein in Mycobacterium tuberculosis (Mtb) that contributes to genome organization and dormancy adaptation. MDP1 consists of a structured HU-like region (HUR), and a post-translational modifications (PTMs)-enriched intrinsically disordered region (IDR), that regulate its function. While its role in DNA condensation is well established, how MDP1 interacts with RNA remains unclear, despite growing recognition of transcriptional regulation during dormancy. Here, by using total RNA from E. coli as a model substrate, we investigated whether MDP1 induces RNA condensation. Our high-speed AFM and optical microscopy analysis shows that native MDP1 from Mtb, rich in PTMs, forms globular RNA condensates. In contrast, MDP1 expressed in E. coli , which lacks PTMs, induces chain-like RNA condensates. Domain-specific analysis revealed that the IDR, the synergy between the IDR and HUR, and PTMs are essential for MDP1-induced RNA condensation. These findings suggest that MDP1 mediates RNA organization during dormancy.
Open AccessMycobacterial DNA-binding protein 1 (MDP1) induces RNA condensation as revealed by high-speed AFM
Mycobacterial DNA-binding protein 1 (MDP1) is a histone-like protein in Mycobacterium tuberculosis (Mtb) that contributes to genome organization and dormancy adaptation. MDP1 consists of a structured HU-like region (HUR), and a post-translational modifications (PTMs)-enriched intrinsically disordered region (IDR), that regulate its function. While its role in DNA condensation is well established, how MDP1 interacts with RNA remains unclear, despite growing recognition of transcriptional regulation during dormancy. Here, by using total RNA from E. coli as a model substrate, we investigated whether MDP1 induces RNA condensation. Our high-speed AFM and optical microscopy analysis shows that native MDP1 from Mtb, rich in PTMs, forms globular RNA condensates. In contrast, MDP1 expressed in E. coli , which lacks PTMs, induces chain-like RNA condensates. Domain-specific analysis revealed that the IDR, the synergy between the IDR and HUR, and PTMs are essential for MDP1-induced RNA condensation. These findings suggest that MDP1 mediates RNA organization during dormancy.
- Open Access
- 1 January 2025
- Published by ASEAN Institute for Health Development in Journal of Public Health and Development
- Vol. 23 (1) , 329-347
Penetration levels and concentration of bedaquiline and clofazimine into the brain parenchyma compared with those in blood plasma: a systematic review and individual case report analysis
The absence of a clear summary of the pharmacokinetic-pharmacodynamic (PK/PD) properties of bedaquiline (Bdq) and clofazimine (Cfz) has limited their use in treating tuberculosis meningitis. This study is the first to summarize the pharmacokinetics and pharmacodynamics of Bdq and Cfz in the cerebrospinal fluid (CSF) and serum. Despite the few reports and studies conducted, we need clear evidence of the PK/PD properties to believe why these drugs must be considered. The included studies report the PK/PD properties of Bedaquiline and or Clofazimine in the blood plasma and or in the brain parenchyma. We exclude non-English articles, papers from non-English speaking countries, and publications before 2000. In this systematic review, we searched articles from PubMed, Scopus, Web of Science, and Google Scholar for studies published from 2000 to Sept 20th, 2023 that assessed treatments and experiments including using bedaquiline “AND” “OR” clofazimine. We also reported studies that included animals in the experimental setting. The risk of Bias in the extracted data was independently assessed by the authors via the EQUATOR (Enhancing the Quality and Transparency of Health Research) study protocol and visualized with Robvis tools. We found nine studies that were suitable for our inclusion criteria. Among nine studies we reviewed, Bedaquiline has a better penetrating ability into the brain parenchyma and central nervous system (CNS) and yields a higher concentration than clofazimine. This study has limitations, including the use of a combination of both drugs where few reports are available. Moreover, further studies are needed to evaluate the efficacy of Bdq and Cfz in the treatment of TBM. All studies were carried out systematically following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and were registered in the PROSPERO database CRD42023466389.
- 1 January 2025
- Published by ASEAN Institute for Health Development in Journal of Public Health and Development
- Vol. 23 (1) , 329-347
Open AccessPenetration levels and concentration of bedaquiline and clofazimine into the brain parenchyma compared with those in blood plasma: a systematic review and individual case report analysis
The absence of a clear summary of the pharmacokinetic-pharmacodynamic (PK/PD) properties of bedaquiline (Bdq) and clofazimine (Cfz) has limited their use in treating tuberculosis meningitis. This study is the first to summarize the pharmacokinetics and pharmacodynamics of Bdq and Cfz in the cerebrospinal fluid (CSF) and serum. Despite the few reports and studies conducted, we need clear evidence of the PK/PD properties to believe why these drugs must be considered. The included studies report the PK/PD properties of Bedaquiline and or Clofazimine in the blood plasma and or in the brain parenchyma. We exclude non-English articles, papers from non-English speaking countries, and publications before 2000. In this systematic review, we searched articles from PubMed, Scopus, Web of Science, and Google Scholar for studies published from 2000 to Sept 20th, 2023 that assessed treatments and experiments including using bedaquiline “AND” “OR” clofazimine. We also reported studies that included animals in the experimental setting. The risk of Bias in the extracted data was independently assessed by the authors via the EQUATOR (Enhancing the Quality and Transparency of Health Research) study protocol and visualized with Robvis tools. We found nine studies that were suitable for our inclusion criteria. Among nine studies we reviewed, Bedaquiline has a better penetrating ability into the brain parenchyma and central nervous system (CNS) and yields a higher concentration than clofazimine. This study has limitations, including the use of a combination of both drugs where few reports are available. Moreover, further studies are needed to evaluate the efficacy of Bdq and Cfz in the treatment of TBM. All studies were carried out systematically following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and were registered in the PROSPERO database CRD42023466389.
- Open Access
- 21 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-19
Recombinant mycobacterial DNA-binding protein 1 with post-translational modifications boosts IFN-gamma production from BCG-vaccinated individuals’ blood cells in combination with CpG-DNA
Tuberculosis remains a large health threat, despite the availability of the tuberculosis vaccine, BCG. As BCG efficacy gradually decreases from adolescence, BCG-Prime and antigen-booster may be an efficient strategy to confer vaccine efficacy. Mycobacterial DNA-binding protein 1 (MDP1, namely Rv2986c, hupB or HU) is a major Mycobacterium tuberculosis protein that induces vaccine-efficacy by co-administration with CpG DNA. To produce MDP1 for booster-vaccine use, we have created recombinant MDP1 produced in both Escherichia coli (eMDP1) and Mycolicibacterium smegmatis (mMDP1), an avirulent rapid-growing mycobacteria. We tested their immunogenicity by checking interferon (IFN)-gamma production by stimulated peripheral blood cells derived from BCG-vaccinated individuals. Similar to native M. tuberculosis MDP1, we observed that most lysin resides in the C-terminal half of mMDP1 are highly methylated. In contrast, eMDP1 had less post-translational modifications and IFN-gamma stimulation. mMDP1 stimulated the highest amount of IFN-gamma production among the examined native M. tuberculosis proteins including immunodominant MPT32 and Antigen 85 complex. MDP1-mediated IFN-gamma production was more strongly enhanced when combined with a new type of CpG DNA G9.1 than any other tested CpG DNAs. Taken together, these results suggest that the combination of mMDP1 and G9.1 possess high potential use for human booster vaccine against tuberculosis.
- 21 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-19
Open AccessRecombinant mycobacterial DNA-binding protein 1 with post-translational modifications boosts IFN-gamma production from BCG-vaccinated individuals’ blood cells in combination with CpG-DNA
Tuberculosis remains a large health threat, despite the availability of the tuberculosis vaccine, BCG. As BCG efficacy gradually decreases from adolescence, BCG-Prime and antigen-booster may be an efficient strategy to confer vaccine efficacy. Mycobacterial DNA-binding protein 1 (MDP1, namely Rv2986c, hupB or HU) is a major Mycobacterium tuberculosis protein that induces vaccine-efficacy by co-administration with CpG DNA. To produce MDP1 for booster-vaccine use, we have created recombinant MDP1 produced in both Escherichia coli (eMDP1) and Mycolicibacterium smegmatis (mMDP1), an avirulent rapid-growing mycobacteria. We tested their immunogenicity by checking interferon (IFN)-gamma production by stimulated peripheral blood cells derived from BCG-vaccinated individuals. Similar to native M. tuberculosis MDP1, we observed that most lysin resides in the C-terminal half of mMDP1 are highly methylated. In contrast, eMDP1 had less post-translational modifications and IFN-gamma stimulation. mMDP1 stimulated the highest amount of IFN-gamma production among the examined native M. tuberculosis proteins including immunodominant MPT32 and Antigen 85 complex. MDP1-mediated IFN-gamma production was more strongly enhanced when combined with a new type of CpG DNA G9.1 than any other tested CpG DNAs. Taken together, these results suggest that the combination of mMDP1 and G9.1 possess high potential use for human booster vaccine against tuberculosis.
- Open Access
- 4 December 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (2) , 816-830
Dynamic action of an intrinsically disordered protein in DNA compaction that induces mycobacterial dormancy
Mycobacteria are the major human pathogens with the capacity to become dormant persisters. Mycobacterial DNA-binding protein 1 (MDP1), an abundant histone-like protein in dormant mycobacteria, induces dormancy phenotypes, e.g. chromosome compaction and growth suppression. For these functions, the polycationic intrinsically disordered region (IDR) is essential. However, the disordered property of IDR stands in the way of clarifying the molecular mechanism. Here we clarified the molecular and structural mechanism of DNA compaction by MDP1. Using high-speed atomic force microscopy, we observed that monomeric MDP1 bundles two adjacent DNA duplexes side-by-side via IDR. Combined with coarse-grained molecular dynamics simulation, we revealed the novel dynamic DNA cross-linking model of MDP1 in which a stretched IDR cross-links two DNA duplexes like double-sided tape. IDR is able to hijack HU function, resulting in the induction of strong mycobacterial growth arrest. This IDR-mediated reversible DNA cross-linking is a reasonable model for MDP1 suppression of the genomic function in the resuscitable non-replicating dormant mycobacteria.
- 4 December 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (2) , 816-830
Open AccessDynamic action of an intrinsically disordered protein in DNA compaction that induces mycobacterial dormancy
Mycobacteria are the major human pathogens with the capacity to become dormant persisters. Mycobacterial DNA-binding protein 1 (MDP1), an abundant histone-like protein in dormant mycobacteria, induces dormancy phenotypes, e.g. chromosome compaction and growth suppression. For these functions, the polycationic intrinsically disordered region (IDR) is essential. However, the disordered property of IDR stands in the way of clarifying the molecular mechanism. Here we clarified the molecular and structural mechanism of DNA compaction by MDP1. Using high-speed atomic force microscopy, we observed that monomeric MDP1 bundles two adjacent DNA duplexes side-by-side via IDR. Combined with coarse-grained molecular dynamics simulation, we revealed the novel dynamic DNA cross-linking model of MDP1 in which a stretched IDR cross-links two DNA duplexes like double-sided tape. IDR is able to hijack HU function, resulting in the induction of strong mycobacterial growth arrest. This IDR-mediated reversible DNA cross-linking is a reasonable model for MDP1 suppression of the genomic function in the resuscitable non-replicating dormant mycobacteria.